Compare CPRX & RUN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CPRX | RUN |
|---|---|---|
| Founded | 2002 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Industrial Machinery/Components |
| Sector | Health Care | Miscellaneous |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.4B | 3.1B |
| IPO Year | 2006 | 2015 |
| Metric | CPRX | RUN |
|---|---|---|
| Price | $31.28 | $16.60 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 20 |
| Target Price | ★ $35.00 | $18.80 |
| AVG Volume (30 Days) | 2.9M | ★ 7.7M |
| Earning Date | 05-11-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 28.24 | ★ 113.35 |
| EPS | 0.50 | ★ 0.62 |
| Revenue | $119,072,803.00 | ★ $858,578,000.00 |
| Revenue This Year | $9.20 | $2.81 |
| Revenue Next Year | $10.51 | $4.54 |
| P/E Ratio | $62.58 | ★ $25.57 |
| Revenue Growth | ★ 16.39 | 12.97 |
| 52 Week Low | $19.05 | $5.38 |
| 52 Week High | $32.56 | $22.44 |
| Indicator | CPRX | RUN |
|---|---|---|
| Relative Strength Index (RSI) | 72.86 | 70.01 |
| Support Level | $31.00 | $15.48 |
| Resistance Level | $31.33 | $16.90 |
| Average True Range (ATR) | 0.08 | 0.87 |
| MACD | -0.19 | 0.25 |
| Stochastic Oscillator | 81.94 | 97.29 |
Catalyst Pharmaceuticals Inc is a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing, and commercializing novel high-quality medicines for patients living with rare and difficult to treat diseases. The Company sells three commercial stage drug products, FIRDAPSE (amifampridine), AGAMREE (vamorolone), and FYCOMPA (perampanel). The Company is currently seeking to further expand its product portfolio, with a focus on acquiring the rights to immediately and near-term accretive assets to treat rare (orphan) diseases across therapeutic areas, including clinical-stage opportunities with established proof of concept.
Sunrun is engaged in the design, development, installation, sale, ownership, and maintenance of residential solar energy systems in the United States. The company acquires customers directly and through relationships with various solar and strategic partners. The solar systems are constructed by Sunrun or by Sunrun's partners and are owned by the company. Sunrun's customers typically enter into 20- to 25-year agreements to utilize its solar energy system. The company also sells solar energy systems and products, such as panels and racking, and solar leads generated to customers.